Abiomed, Inc.
ABMD · NASDAQ
3/31/2022 | 3/31/2021 | 3/31/2020 | 3/31/2019 | |
|---|---|---|---|---|
| Market Cap | $15 | $14 | $7 | $12 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $15 | $14 | $6 | $12 |
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 21.7% | 0.8% | 9.3% | – |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 81.8% | 80.9% | 82% | 83.2% |
| EBITDA | $1 | $0 | $0 | $0 |
| % Margin | 48.5% | 29.1% | 30.6% | 30% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 13.2% | 26.6% | 24.1% | 33.7% |
| EPS Diluted | 2.98 | 4.94 | 4.43 | 5.61 |
| % Growth | -39.7% | 11.5% | -21% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |